Navigation Links
/C O R R E C T I O N from Source -- Resverlogix Corp./

In TO339 transmitted at 1617e today, an error occurred in the first paragraph. The timing of the live teleconference should have read: "9:00 am

MDT" and not "9:00 pm MDT". Corrected copy follows:

Resverlogix Notice of Conference Call & Webcast

TSX Exchange Symbol: RVX

CALGARY, May 1 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that it will host a live teleconference on May 8, 2008 at 9:00 am MDT to provide a year-end update on both the science and the business aspects of the Company. Following the presentation there will be a live question and answer session.

The webcast can be accessed at the following link: or on Resverlogix's website at:
Participants can also dial in for the conference call:

Dial information is as follows:

International Dial In: 1 604 638 5340

North America Toll Free: 1 800 319 4610

The webcast will be available on the Resverlogix website for replay for a period of 10 days after the event.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ETEX Announces Supply Agreement with AlloSource
2. One4One Campaign to Raise $1 Million to Improve Cervical Cancer Education and Resources
3. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
4. United BioSource Acquires Leading Publication Planning Software and Services Company
5. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
6. Nova Biosource Fuels Expands Senior Executive Team
7. LUMEDX Updates Real-Time Patient and Resource Scheduler for Healthcare Systems
8. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
9. Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility
10. New FTMS System From Varian, Inc. Offers Switchable LC and GC Sources and True Triple Quadrupole Capabilities
11. Honey bee invaders exploit the genetic resources of their predecessors
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology:
(Date:6/9/2016)... Finland , June 9, 2016 ... National Police deploy Teleste,s video security solution to ensure the ... France during the major tournament ... data communications systems and services, announced today that its video ... Prefecture to back up public safety across the ...
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/12/2016)... , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
Breaking Biology News(10 mins):